Trial · NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
NCT00493454, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2013-05-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas. Trials, record NCT00493454. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00493454
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
- NCT number
- NCT00493454
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Lymphoma
- Interventions
- Zevalin, Rituximab, ^111 In Ibritumomab Tiuxetan
- First posted
- 2007-06-28
- Last updated
- 2013-05-31
- Results first posted
- 2013-05-31
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | Evaluation 4 weeks after administration of Zevalin up to 3 years | Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum. Complete response (CR) must have disappearance of all target and non-target lesions. Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate | Evaluation 4 weeks after administration of Zevalin up to 3 years | One participant did not receive treatment and was excluded from analysis. | proportion of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate | Ibritumomab Tiuxetan + Rituximab | 0.8 | proportion of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ibritumomab Tiuxetan + Rituximab | 6 | |
| Overall Study | COMPLETED | Ibritumomab Tiuxetan + Rituximab | 5 | |
| Overall Study | NOT COMPLETED | Ibritumomab Tiuxetan + Rituximab | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ibritumomab Tiuxetan + Rituximab | 2 | 5 | |
| other | Neutropenia | Blood and lymphatic system disorders | Ibritumomab Tiuxetan + Rituximab | 2 | 5 | |
| other | Fatigue | General disorders | Ibritumomab Tiuxetan + Rituximab | 1 | 5 | |
| serious | Neutropenia | Blood and lymphatic system disorders | Ibritumomab Tiuxetan + Rituximab | 1 | 5 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ibritumomab Tiuxetan + Rituximab | ||
| Total, other adverse events | Ibritumomab Tiuxetan + Rituximab | 5 | 5 |
| Total, serious adverse events | Ibritumomab Tiuxetan + Rituximab | 1 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00493454
GET https://conductscience.org/api/trials/v1/NCT00493454/registered